Suzhou ASTRABIO Co., Ltd.

【Abstract】 Genetic investigations and associations with plasma biomarkers of dementia with Lewy bodies (DLB) in East Asian populations are lacking. The aim of our study is to identify candidate patho...

【Background】 Ethnic variations and detection methods may lead to differences in diagnostic biomarkers of dementia, and few comparative studies have evaluated the six plasma biomarkers of Alzheimer’s ...

【Background】 Alzheimer’s disease (AD) involves complex alterations in biological pathways, making comprehensive blood biomarkers crucial for accurate and earlier diagnosis. However, the cost-effectiv...

【Editor’s summary】： One of the major causes of neurodegeneration in patients with Parkinson’s disease (PD) is the intracellular accumulation of α-synuclein in neurons. Wu et al. investigated the m...

【Highlights】： •Plasma markers (GFAP and NfL) and regional SUVRs of 18F-AV-1451 PET could distinguish patients with MCI from CN in two cohorts. •Increased tau deposition in the amygdala and l...

【Introduction】： Frontotemporal dementia (FTD) is characterized by phenotypic and genetic heterogeneities. However, reports on the large Chinese FTD cohort are lacking. 【Meth...

【Aims】： Apply established cerebrospinal fluid (CSF) and serum biomarkers and novel combined indicators based on the amyloid/tau/neurodegeneration (ATN) framework to improve diagnostic and pr...

【Background】： Previous studies have demonstrated that early intervention was the best plan to inhibit the progression of Alzheimer’s disease (AD), which relied on the discovery of early diagnostic bi...